NCT01449786View on ClinicalTrials.gov

Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 14, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

December 20, 2016

Conditions
Birch Pollen Related Apple AllergyBirch Pollen Allergy
Interventions
DRUG

rMal d 1

25 µg daily as sublingually administered drops, 16 weeks

DRUG

rBet v 1

25 µg daily administered sublingually as drops over 16 weeks

OTHER

placebo drops

25 µg of placebo Drops daily administered sublingually over 16 weeks

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
collaborator

Austrian Science Fund (FWF)

OTHER

lead

Medical University of Vienna

OTHER

NCT01449786 - Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy | Biotech Hunter | Biotech Hunter